Effect of fenfluramine-induced increases in serotonin release on [ 18F]MPPF binding: A continuous infusion PET study in conscious monkeys

Synapse

Volumn 59, Issue 1, 2006, Pages 18-26

  De Udo Haes, Joanna I ^a   Harada, Norihiro ^b   Elsinga, Philip H ^a   Maguire, R Paul ^a,c   Tsukada, Hideo ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b HAMAMATSU PHOTONICS K K   (Japan)

^c PFIZER INC   (United States)

Author keywords

5 HT1A receptor; 18F MPPF; Affinity; Fenfluramine; Microdialysis; Monkeys; PET; Serotonin

Indexed keywords

4 (2' METHOXYPHENYL) 1 [2' (N 2'' PYRIDINYL) 4 FLUOROBENZAMIDO]ETHYLPIPERAZINE F 18; CARBON 14; FENFLURAMINE; FLUORINE 18; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN; SEROTONIN 1A ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN BLOOD FLOW; CONSCIOUSNESS; CONTINUOUS INFUSION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG UPTAKE; FRONTAL CORTEX; HALF LIFE TIME; HIPPOCAMPUS; LIGAND BINDING; MALE; MICRODIALYSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAPHE NUCLEUS; RECEPTOR AFFINITY; RHESUS MONKEY; SEROTONIN RELEASE; STATISTICAL ANALYSIS;

ANIMALS; AUTORADIOGRAPHY; BRAIN; BRAIN CHEMISTRY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FENFLURAMINE; MACACA MULATTA; MAGNETIC RESONANCE IMAGING; MALE; MICRODIALYSIS; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; PYRIDINES; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; WAKEFULNESS;

EID: 28244475051     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.20209     Document Type: Article

References (55)

1. Amat J, Matus-Amat P, Watkins LR, Maier SF. 1998. Escapable and inescapable stress differentially and selectively alter extracellular levels of 5-HT in the ventral hippocampus and dorsal periaqueductal gray of the rat. Brain Res 797:12-22.
2. Bantick RA, Rabiner EA, Hirani E, de Vries MH, Hume SP, Grasby PM. 2004. Occupancy of agonist drugs at the 5-HT1A receptor. Neuropsychopharmacology 29:847-859.
3. Bland ST, Hargrave D, Pepin JL, Amat J, Watkins LR, Maier SF. 2003. Stressor controllability modulates stress-induced dopamine and serotonin efflux and morphine-induced serotonin efflux in the medial prefrontal cortex. Neuropsychopharmacology 28:1589-1596.
4. Blier P, de Montigny C. 1998. Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive-compulsive disorder responses. Biol Psychiatry 44:313-323.
5. 3H]propyl- norapomorphine to dopamine receptors in living mouse striatum: occupancy by endogenous dopamine and guanosine triphosphate-free G protein. J Cereb Blood Flow Metab 22:596-604.
6. De-la-Fuente-Fernandez R, Phillips AG, Zamburlini M, Sossi V, Calne DB, Ruth TJ, Stoessl AJ. 2002. Dopamine release in human ventral striatum and expectation of reward. Behav Brain Res 136:359-363.
7. Den Boer JA. 2000, Social anxiety disorder/social phobia: epidemiology, diagnosis, neurobiology, and treatment. Compr Psychiatry 41:405-415.
8. Endres CJ, Carson RE. 1998. Assessment of dynamic neurotransmitter changes with bolus or infusion delivery of neuroreceptor ligands. J Cereb Blood Flow Metab 18:1196-1210.
9. 11C]WAY-100635 binding to 5-HT1A receptors in the primate brain. Psychopharmacology (Berl) 133:196-202.
10. 11C] raclopride binding in anesthetized cats. Neuropsychopharmacology 27:72-84.
11. Gozlan H, Thibault S, Laporte AM, Lima L, Hamon M. 1995. The selective 5-HT1A antagonist radioligand [3H]WAY 100635 labels both G-protein-coupled and free 5-HT1A receptors in rat brain membranes. Eur J Pharmacol 288:173-186.
12. 11C]WAY-100635. Brain Res 745:96-108.
13. 18F]fluoroethyl)nortropane) as a dopamine transporter ligand: a PET study in the conscious monkey brain. Synapse 54:37-45.
14. 11C]raclopride binding in the striatum of the awake cat: effects of anaesthetics and role of cerebral blood flow. Eur J Nucl Med Mol Imaging 30:141-148.
15. 11C] WAY 100635 to 5-HT1A receptors in rat brain, assessed using in vivo microdialysis and PET after fenfluramine. Synapse 41:150-159.
16. 11C]raclopride binding. J Cereb Blood Flow Metab 18:941-950.
17. Kalen P, Rosegren E, Lindvall O, Bjorklund A. 1989. Hippocampal noradrenaline and serotonin release over 24 hours as measured by the dialysis technique in freely moving rats: correlation to behavioural activity state, effect of handling and tail-pinch. Eur J Neurosci 1:181-188.
18. Kapur S, Remington G. 2001. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med 52:503-517.
19. 3H]WAY-100635, a selective 5-HT1A receptor antagonist. Brain Res 673:217-225.
20. Klotz KN, Vogt H, Tawfik-Schlieper H. 1991. Comparison of A1 adenosine receptors in brain from different species by radioligand binding and photoaffinity labelling. Naunyn Schmiedebergs Arch Pharmacol 343:196-201.
21. Kung HF, Frederick D, Kim HJ, McElgin W, Kung MP, Mu M, Mozley PD, Vessotskie JM, Stevenson DA, Kushner SA, Zhuang ZP. 1996. In vivo SPECT imaging of 5-HT1A receptors with [123I]p-MPPI in nonhuman primates. Synapse 24:273-281.
22. Laruelle M. 2000. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20:423-451.
23. 11C]WAY- 100635: effect of endogenous serotonin. Synapse 40:122-129.
24. Mengod G, Vilaro MT, Raurich A, Lopez-Gimenez JF, Cortes R, Palacios JM. 1996. 5-HT receptors in mammalian brain: receptor autoradiography and in situ hybridization studies of new ligands and newly identified receptors. Histochem J 28:747-758.
25. Momosaki S, Hatano K, Kawasumi Y, Kato T, Hosoi R, Kobayashi K, Inoue O, Ito K. 2004. Rat-PET study without anesthesia: anesthetics modify the dopamine D(1) receptor binding in rat brain. Synapse 54:207-213.
26. 1A receptor in rat hippocampus. Brain Res 590:229-238.
27. 11C]-raclopride. Synapse 52:188-208.
28. Nénonéné EK, Radja F, Carli M, Grondin L, Reader TA. 1994. Heterogeneity of cortical and hippocampal 5-HT1A receptors: a reappraisal of homogenate binding with 8-[3H]hydroxydipropylaminotetralin. J Neurochem 62:1822-1834.
29. Newman-Tancredi A, Chaput C, Verriele L, Millan MJ. 1996. S 15535 and WAY 100,635 antagonise 5-HT-stimulated [35S]GTP γ-S binding at cloned human 5-HT1A receptors. Eur J Pharmacol 307:107-111.
30. Ohba H, Harada N, Nishiyama S, Fukumoto D, Kakiuchi T, Tsukada H. 2004. Application of PET with feedback injection control system for quantification of drug-induced effects on the brain function. In: Tamaki N, Kuge Y, editors. PET and molecular imaging: state of the art and future perspectives. The Netherlands: Elsevier p 202-205.
31. 11C]methylspiperone binding in vivo: positron emission tomography study using conscious rhesus monkey. Brain Res 663:191-198.
32. 11C]WAY-100635-explanation of high signal contrast in PET and an aid to biomathematical modelling. Nucl Med Biol 25:215-223.
33. 11C]Desmethyl-WAY-100635 (DWAY) is a potent and selective radioligand for central 5-HT1A receptors in vitro and in vivo. Eur J Nucl Med 25:338-346.
34. 18F]p-MPPF: a radiolabeled antagonist for the study of 5-HT1A receptors with PET. Nucl Med Biol 27:467-471.
35. 18F]MPPF), a new serotonin 5-HT(1A) antagonist for positron emission tomography: an in vivo study in rats. J Neurochem 75:803-811.
36. 11C] raclopride. J Neurosci 24:2825-2831.
37. 11C]WAY-100635 binding to 5-HT(1A) receptors in normal male volunteers: normative data and relationship to methodological, demographic, physiological, and behavioral variables. Neuroimage 15:620-632.
38. 2 dopamine receptor autoradiography: high percentage of high-affinity agonist sites and increased nucleotide sensitivity in tissue sections. Brain Res 383:121-128.
39. Seeman P. 2002. Atypical antipsychotics: mechanism of action. Can J Psychiatry 47:27-38.
40. 2 and other G-linked receptors. Synapse 50:35-40.
41. 18F]-MPPF: a potential radioligand for PET studies of 5-HT1A receptors in humans. Synapse 25:147-154.
42. Snider R, Lee JC. 1961. A stereotactic atlas of the monkey brain (Macaca mulatta). Chicago: Chicago University Press.
43. Takechi H, Onoe H, Imamura K, Onoe K, Kakiuchi T, Nishiyama S, Yoshikawa E, Mori S, Kosugi T, Okada H, Tsukada H, Watanabe Y. 1994. Brain activation study by use of positron emission tomography in unanesthetized monkeys. Neurosci Lett 182:279-282.
44. 11C]WAY-100635 PET investigation in healthy volunteers. Am J Psychiatry 158s:1326-1328.
45. 11C]WAY-100635 in conscious monkeys. Synapse 42:242-251.
46. 11C]raclopride binding in unanesthetized monkeys. Synapse 45:207-212.
47. 18F]MPPF binding. Synapse 46:108-115.
48. 18F]MPPF binding in rat brain: fenfluramine vs. the combination of citalopram and ketanserin. Neuropsychopharmacology 30:1624-1631.
49. 11C]raclopride in the human brain. Synapse 16:255-262.
50. Watanabe M, Okada H, Shimizu K, Omura T, Yoshikawa E, Kosugi T, Mori S, Yamashita T. 1997. A high resolution animal PET scanner using compact PS-PMT detectors. IEEE Trans Nucl Sci 47:1277-1282.
51. Watson J, Collin L, Ho M, Riley G, Scott C, Selkirk JV, Price GW. 2000. 5-HT(1A) receptor agonist-antagonist binding affinity difference as a measure of intrinsic activity in recombinant and native tissue systems. Br J Pharmacol 130:1108-1114.
52. Yoder KK, Wang C, Morris ED. 2004. Change in binding potential as a quantitative index of neurotransmitter release is highly sensitive to relative timing and kinetics of the tracer and the endogenous ligand. J Nucl Med 45:903-911.
53. Zald DH, Boileau I, El-Dearedy W, Gunn R, McGlone F, Dichter GS, Dagher A. 2004. Dopamine transmission in the human striatum during monetary reward tasks. J Neurosci 24:4105-4112.
54. Zhuang ZP, Kung MP, Kung HF. 1994. Synthesis and evaluation of 4-(2′-methoxyphenyl)-1-[2′-[N-(2″-pyridinyl)-p-iodobenzamido] ethyl] piperazine (p-MPPI): a new iodinated 5-HT1A ligand. J Med Chem 37:1406-1407.
55. 18F-MPPF in the rat hippocampus: kinetic β measurements combined with microdialysis. J Neurochem 80:278-286.